Reported Earnings • Apr 23
First quarter 2026 earnings: Revenues and EPS in line with analyst expectations First quarter 2026 results: EPS: CN¥0.41 (up from CN¥0.37 in 1Q 2025). Revenue: CN¥6.09b (up 1.3% from 1Q 2025). Net income: CN¥499.5m (up 11% from 1Q 2025). Profit margin: 8.2% (up from 7.5% in 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Apr 23
Yifeng Pharmacy Chain Co., Ltd., Annual General Meeting, May 22, 2026 Yifeng Pharmacy Chain Co., Ltd., Annual General Meeting, May 22, 2026, at 14:00 China Standard Time. Location: 3F, No. 68, Jinzhou Avenue, Changsha, Hunan China Announcement • Mar 30
Yifeng Pharmacy Chain Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026 Yifeng Pharmacy Chain Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026 Announcement • Dec 26
Yifeng Pharmacy Chain Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026 Yifeng Pharmacy Chain Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: EPS: CN¥0.28 (up from CN¥0.26 in 3Q 2024). Revenue: CN¥5.56b (up 2.0% from 3Q 2024). Net income: CN¥344.5m (up 10% from 3Q 2024). Profit margin: 6.2% (up from 5.7% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) also missed analyst estimates by 7.4%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Yifeng Pharmacy Chain Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Yifeng Pharmacy Chain Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Reported Earnings • Aug 31
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Second quarter 2025 results: EPS: CN¥0.36 (up from CN¥0.33 in 2Q 2024). Revenue: CN¥5.71b (down 1.4% from 2Q 2024). Net income: CN¥430.6m (up 10% from 2Q 2024). Profit margin: 7.5% (up from 6.8% in 2Q 2024). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 7.5%. Earnings per share (EPS) also missed analyst estimates by 3.3%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Jun 30
Yifeng Pharmacy Chain Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025 Yifeng Pharmacy Chain Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Announcement • Jun 24
Yifeng Pharmacy Chain Co., Ltd.(SHSE:603939) dropped from Shanghai Stock Exchange 180 Value Index Yifeng Pharmacy Chain Co., Ltd. has been removed from Shanghai Stock Exchange 180 Value Index. Reported Earnings • Apr 30
Full year 2024 earnings released: EPS: CN¥1.26 (vs CN¥1.17 in FY 2023) Full year 2024 results: EPS: CN¥1.26 (up from CN¥1.17 in FY 2023). Revenue: CN¥24.1b (up 6.5% from FY 2023). Net income: CN¥1.53b (up 8.3% from FY 2023). Profit margin: 6.4% (up from 6.3% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Announcement • Apr 29
Yifeng Pharmacy Chain Co., Ltd., Annual General Meeting, May 29, 2025 Yifeng Pharmacy Chain Co., Ltd., Annual General Meeting, May 29, 2025, at 14:00 China Standard Time. Announcement • Mar 28
Yifeng Pharmacy Chain Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025 Yifeng Pharmacy Chain Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Announcement • Dec 27
Yifeng Pharmacy Chain Co., Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025 Yifeng Pharmacy Chain Co., Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025 Reported Earnings • Oct 31
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: EPS: CN¥0.26 (up from CN¥0.24 in 3Q 2023). Revenue: CN¥5.46b (up 5.3% from 3Q 2023). Net income: CN¥312.8m (up 6.4% from 3Q 2023). Profit margin: 5.7% (in line with 3Q 2023). Revenue missed analyst estimates by 4.8%. Earnings per share (EPS) also missed analyst estimates by 2.7%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥22.61, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 12x in the Consumer Retailing industry in China. Total loss to shareholders of 24% over the past three years. Announcement • Sep 30
Yifeng Pharmacy Chain Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Yifeng Pharmacy Chain Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to CN¥23.20, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 12x in the Consumer Retailing industry in China. Total loss to shareholders of 23% over the past three years. Price Target Changed • Sep 04
Price target decreased by 8.0% to CN¥39.55 Down from CN¥42.99, the current price target is an average from 13 analysts. New target price is 104% above last closing price of CN¥19.41. Stock is down 33% over the past year. The company is forecast to post earnings per share of CN¥1.33 for next year compared to CN¥1.17 last year. Reported Earnings • Aug 31
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: EPS: CN¥0.33 (up from CN¥0.30 in 2Q 2023). Revenue: CN¥5.79b (up 6.5% from 2Q 2023). Net income: CN¥391.0m (up 6.0% from 2Q 2023). Profit margin: 6.8% (in line with 2Q 2023). Revenue missed analyst estimates by 9.2%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Announcement • Jun 28
Yifeng Pharmacy Chain Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Yifeng Pharmacy Chain Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 Price Target Changed • Jun 08
Price target decreased by 15% to CN¥45.15 Down from CN¥52.97, the current price target is an average from 13 analysts. New target price is 29% above last closing price of CN¥35.00. Stock is up 21% over the past year. The company is forecast to post earnings per share of CN¥1.48 for next year compared to CN¥1.17 last year. Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥36.67, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 21x in the Consumer Retailing industry in China. Total loss to shareholders of 14% over the past three years. Reported Earnings • May 04
Full year 2023 earnings released: EPS: CN¥1.40 (vs CN¥1.26 in FY 2022) Full year 2023 results: EPS: CN¥1.40 (up from CN¥1.26 in FY 2022). Revenue: CN¥22.6b (up 14% from FY 2022). Net income: CN¥1.41b (up 12% from FY 2022). Profit margin: 6.3% (down from 6.4% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Apr 30
Yifeng Pharmacy Chain Co., Ltd., Annual General Meeting, May 20, 2024 Yifeng Pharmacy Chain Co., Ltd., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: 3F, No. 68, Jinzhou Avenue, Changsha, Hunan China Announcement • Mar 29
Yifeng Pharmacy Chain Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024 Yifeng Pharmacy Chain Co., Ltd. announced that they will report Q1, 2024 results on Apr 29, 2024 Announcement • Dec 29
Yifeng Pharmacy Chain Co., Ltd. to Report Fiscal Year 2023 Results on Apr 29, 2024 Yifeng Pharmacy Chain Co., Ltd. announced that they will report fiscal year 2023 results on Apr 29, 2024 Reported Earnings • Aug 30
Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint Second quarter 2023 results: EPS: CN¥0.36 (up from CN¥0.30 in 2Q 2022). Revenue: CN¥5.44b (up 18% from 2Q 2022). Net income: CN¥368.7m (up 21% from 2Q 2022). Profit margin: 6.8% (up from 6.6% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.6%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Announcement • Jun 28
Yifeng Pharmacy Chain Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023 Yifeng Pharmacy Chain Co., Ltd. announced that they will report first half, 2023 results on Aug 30, 2023 Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment deteriorates as stock falls 33% After last week's 33% share price decline to CN¥34.41, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total loss to shareholders of 41% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥62.81 per share. Buying Opportunity • May 24
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 15%. The fair value is estimated to be CN¥62.81, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 46% in 2 years. Earnings is forecast to grow by 41% in the next 2 years. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 29
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2022 results: EPS: CN¥0.35 (up from CN¥0.26 in 3Q 2021). Revenue: CN¥4.60b (up 28% from 3Q 2021). Net income: CN¥247.2m (up 29% from 3Q 2021). Profit margin: 5.4% (up from 5.3% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 11%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 31
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Second quarter 2022 results: EPS: CN¥0.42 (up from CN¥0.38 in 2Q 2021). Revenue: CN¥4.60b (up 24% from 2Q 2021). Net income: CN¥304.2m (up 16% from 2Q 2021). Profit margin: 6.6% (down from 7.1% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 3.1%. Earnings per share (EPS) also surpassed analyst estimates by 3.3%. Over the next year, revenue is forecast to grow 25%, compared to a 17% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Announcement • May 28
Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) completed the acquisition of a 51% stake in Hunan Jiuzhitang Pharmaceutical Co., Ltd. from Jiuzhitang Co., Ltd. (SZSE:000989). Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) agreed to acquire 51% of stake in Hunan Jiuzhitang Pharmaceutical Co., Ltd. from Jiuzhitang Co., Ltd. (SZSE:000989) for approximately CNY 200 million on April 23, 2022. Within 7 working days after the agreement signing, Yifeng Pharmacy Chain Co., Ltd. will pay a deposit of CNY 80 million. After the completion of the transfer, within 7 working days after receiving the Company’s payment notice, Yifeng Pharmacy Chain Co., Ltd. will pay CNY 60 million. 4 months after the second payment, after there is no objection to price adjustments (if any), within 7 working days after receiving the Company’s payment notice, Yifeng Pharmacy Chain Co., Ltd. will pay the remaining amount. Hunan Jiuzhitang has a total assets of CNY 554 million and net assets of CNY 144 million as of March 31, 2022. This has been approved in the 9th Meeting of Yifeng Pharmacy's 4th Directorate held on April 23, 2022, and does not need the shareholders’ approval. This is subject to Jiuzhitang Co., Ltd.’s shareholders’ approval.
Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) completed the acquisition of a 51% stake in Hunan Jiuzhitang Pharmaceutical Co., Ltd. from Jiuzhitang Co., Ltd. (SZSE:000989) on May 26, 2022. Yifeng Pharmacy Chain has settled the part payment and the remaining amount will be settled according to the agreement. Reported Earnings • May 02
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: CN¥0.38 (up from CN¥0.35 in 1Q 2021). Revenue: CN¥4.15b (up 14% from 1Q 2021). Net income: CN¥272.2m (up 13% from 1Q 2021). Profit margin: 6.6% (in line with 1Q 2021). Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates by 8.4%. Over the next year, revenue is forecast to grow 29%, compared to a 16% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Price Target Changed • May 01
Price target decreased to CN¥64.76 Down from CN¥69.88, the current price target is an average from 9 analysts. New target price is 76% above last closing price of CN¥36.80. Stock is down 47% over the past year. The company is forecast to post earnings per share of CN¥1.64 for next year compared to CN¥1.25 last year. Announcement • Apr 27
Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) agreed to acquire 5% stake in Jiuzhitang Co., Ltd. (SZSE:000989) from Li Zhenguo for CNY 430 million. Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) agreed to acquire 5% stake in Jiuzhitang Co., Ltd. (SZSE:000989) from Li Zhenguo for CNY 430 million on April 23, 2022. under the terms Yifeng Pharmacy Chain Co., Ltd. will acquire 43.46 million shares for CNY 9.85 per share. Within 3 working days after the agreement signing, Yifeng Pharmacy Chain Co., Ltd will make a deposit of 5% of the transfer price. Within 3 working days from the completion of the transfer, the Company will pay the remaining amount. The transaction has been approved in the 9th Meeting of the Company’s 4th Directorate, and does not need the Shareholders’ Approval. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Dec 09
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥51.32, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 22x in the Consumer Retailing industry in China. Total returns to shareholders of 84% over the past three years. Price Target Changed • Dec 02
Price target decreased to CN¥69.45 Down from CN¥74.71, the current price target is an average from 13 analysts. New target price is 56% above last closing price of CN¥44.48. Stock is down 43% over the past year. The company is forecast to post earnings per share of CN¥1.29 for next year compared to CN¥1.12 last year. Reported Earnings • Nov 03
Third quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.25 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥3.59b (up 14% from 3Q 2020). Net income: CN¥191.2m (up 12% from 3Q 2020). Profit margin: 5.3% (down from 5.4% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 27
Second quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.32 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥3.72b (up 14% from 2Q 2020). Net income: CN¥263.5m (up 19% from 2Q 2020). Profit margin: 7.1% (up from 6.8% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Aug 12
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥51.81, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 25x in the Consumer Retailing industry in China. Total returns to shareholders of 81% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥40.74 per share. Price Target Changed • Jun 08
Price target decreased to CN¥68.15 Down from CN¥84.95, the current price target is an average from 10 analysts. New target price is 11% above last closing price of CN¥61.18. Stock is up 2.6% over the past year. Reported Earnings • May 02
First quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.35 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥3.63b (up 19% from 1Q 2020). Net income: CN¥241.3m (up 29% from 1Q 2020). Profit margin: 6.6% (up from 6.1% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year whereas the company’s share price has increased by 28% per year. Is New 90 Day High Low • Feb 26
New 90-day low: CN¥88.10 The company is down 13% from its price of CN¥102 on 27 November 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥91.48 per share. Valuation Update With 7 Day Price Move • Jan 13
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥107, the stock is trading at a trailing P/E ratio of 78.9x, up from the previous P/E ratio of 66.4x. This compares to an average P/E of 34x in the Consumer Retailing industry in China. Total returns to shareholders over the past three years are 249%. Is New 90 Day High Low • Dec 18
New 90-day low: CN¥88.50 The company is down 10.0% from its price of CN¥98.79 on 18 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Consumer Retailing industry, which is also down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥91.56 per share. Price Target Changed • Nov 19
Price target raised to CN¥104 Up from CN¥95.06, the current price target is an average from 9 analysts. The new target price is 5.7% above the current share price of CN¥98.26. As of last close, the stock is up 64% over the past year. Is New 90 Day High Low • Nov 12
New 90-day high: CN¥107 The company is up 21% from its price of CN¥87.80 on 14 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥77.45 per share. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥715.9m, up 36% from the prior year. Total revenue was CN¥12.3b over the last 12 months, up 28% from the prior year. Announcement • Oct 29
Yifeng Pharmacy Chain Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020 Yifeng Pharmacy Chain Co., Ltd. announced that they will report Q3, 2020 results on Oct 30, 2020 Announcement • Jul 10
Yifeng Pharmacy Chain Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020 Yifeng Pharmacy Chain Co., Ltd. announced that they will report first half, 2020 results on Aug 28, 2020 
